Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.34 |
| ▸ | ALPL | P05186 | 2/20 | 0.34 |
| ▸ | XIAP | P98170 | 2/20 | 0.34 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | SLC34A1 | Q06495 | 5/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3093474 | 0.87 | HTT (0.41) | POLBMAPTHTTKDM4EMPO | |
| SCHEMBL2812766 | 0.75 | HTT (0.73) | POLBMAPTHTTMEN1KMT2A | |
| SCHEMBL3084534 | 0.75 | HTT (0.42) | HTT | |
| SCHEMBL3097306 | 0.73 | ADORA2A (0.44) | POLBMEN1KMT2A | |
| SCHEMBL3571457 | 0.66 | MEN1 (0.61) | POLBMAPTHTTKDM4EMEN1 | |
| SCHEMBL28996251 | 0.66 | POLB (0.36) | POLBMAPTKDM4EMEN1KMT2A | |
| SCHEMBL5674953 | 0.65 | NR2E1 (0.39) | HTT | |
| SCHEMBL13430436 | 0.65 | HTT (0.53) | POLBHTTKDM4EMEN1KMT2A | |
| SCHEMBL21568425 | 0.65 | LMNA (0.53) | POLBMAPTHTTKDM4EMEN1 | |
| SCHEMBL115697 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | US | disclosed |
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | US | disclosed |
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | US | disclosed |
| EP-2121662-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008070661-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA1, ADORA2A | POLB 956/4885MAPT 4424/4885HTT 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.